Danielle-Roberts(updated) - Headshot

Danielle Roberts,

MS, MMSc, PA-C

Danielle Roberts,

MS, MMSc, PA-C

Associate Chief of Education, Winship Cancer Institute of Emory University

Danielle-Roberts(updated) - Headshot

Danielle Roberts,

MS, MMSc, PA-C

Associate Chief of Education, Winship Cancer Institute of Emory University

Danielle Roberts serves as the director for the APP Fellowship Program. She graduated from Emory University’s Physician Assistant Program in 2007. Upon graduation, Danielle worked in community oncology before joining the Winship Cancer Institute in 2011.  She has enjoyed working in many oncologic specialties including community oncology, survivorship, GVHD, and in her current position in malignant hematology. Danielle currently serves as the Associate Chief of Education for the Winship Cancer Institute and is Society Leader and adjunct faculty for the Emory University Physician Assistant Program.  She recently graduated from the WHEA Teaching Fellowship and was honored with the 2022 Physician Assistant of the Year by the Emory Physician Assistant program.

Provided by an unrestricted grant from

Danielle-Roberts - Headshot

Danielle's Shared Resources

Balancing Efficacy and Safety: Managing Adverse Events With IMiDs in Multiple Myeloma

Immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide are integral to multiple myeloma (MM) treatment, improving survival and quality of life....
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Comprehensive Advances in Multiple Myeloma: From Diagnosis to Emerging Therapies

Multiple myeloma is a plasma cell cancer that often develops from precursor conditions like monoclonal gammopathy of undetermined significance or smoldering multiple myeloma (SMM)....
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

IsaPd Shows Promise in Dara-R Multiple Myeloma, but Modest PFS Highlights Need for New Therapies

Researchers of a multicenter real-world analysis assessed the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara-R). The study...
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Provided by an unrestricted grant from

Share